Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer

R. V. Iaffaioli, F. Caponigro, A. Tortoriello, G. Facchini, V. Ravo, M. Maccauro, P. Dimitri, F. Crovella, P. Muto

Research output: Contribution to journalArticle

Abstract

43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.

Original languageEnglish
Pages (from-to)1901-1904
Number of pages4
JournalEuropean Journal of Cancer
Volume32
Issue number11
DOIs
Publication statusPublished - Oct 1996

Keywords

  • Accelerated split-course radiotherapy
  • Carboplatin
  • Non-small cell lung cancer
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this